Drug Product Development for the Back of the Eye
197,99 €
versandkostenfrei*

inkl. MwSt.
Sofort lieferbar
Bequeme Ratenzahlung möglich!
ab 9,66 € monatlich
99 °P sammeln

    Gebundenes Buch

This comprehensive volume discusses approaches for a systematic selection of delivery systems for various classes of therapeutic agents including small molecule, protein, and nucleic acid drugs. Specific topics covered in this book include: Solution, suspension, gel, nanoparticle, microparticle, and implant dosage forms Refillable and microneedle devices Intravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of delivery Physical methods including iontophoresis for drug delivery Rational selection of routes of administration and delivery systems Noninvasive and…mehr

Produktbeschreibung
This comprehensive volume discusses approaches for a systematic selection of delivery systems for various classes of therapeutic agents including small molecule, protein, and nucleic acid drugs. Specific topics covered in this book include: Solution, suspension, gel, nanoparticle, microparticle, and implant dosage forms Refillable and microneedle devices Intravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of delivery Physical methods including iontophoresis for drug delivery Rational selection of routes of administration and delivery systems Noninvasive and continuous drug monitoring Regulatory path to drug product development Clinical endpoints for drug product development Emerging and existing drugs and drug targets Drug Product Development for the Back of the Eye is authored by renowned ocular drug delivery experts, representing academic, clinical, and industrial organizations and serves as indispensable resource for ophthalmic researchers, drug formulation scientists, drug delivery and drug disposition scientists, as well as clinicians involved in designing and developing novel therapeutics for the back of the eye diseases. This book is also relevant for students in various disciplines including ophthalmology, pharmaceutical sciences, drug delivery, and biomedical engineering. Refillable and microneedle devices Intravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of delivery Physical methods including iontophoresis for drug delivery Rational selection of routes of administration and delivery systems Noninvasive and continuous drug monitoring Regulatory path to drug product development Clinical endpoints for drug product development Emerging and existing drugs and drug targets Drug Product Development for the Back of the Eye is authored by renowned ocular drug delivery experts, representing academic, clinical, and industrial organizations and serves as indispensable resource for ophthalmic researchers, drug formulation scientists, drug delivery and drug disposition scientists, as well as clinicians involved in designing and developing novel therapeutics for the back of the eye diseases. This book is also relevant for students in various disciplines including ophthalmology, pharmaceutical sciences, drug delivery, and biomedical engineering. Refillable and microneedle devices Intravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of delivery Physical methods including iontophoresis for drug delivery Rational selection of routes of administration and delivery systems Noninvasive and continuous drug monitoring Regulatory path to drug product development Clinical endpoints for drug product development Emerging and existing drugs and drug targets Drug Product Development for the Back of the Eye is authored by renowned ocular drug delivery experts, representing academic, clinical, and industrial organizations and serves as indispensable resource for ophthalmic researchers, drug formulation scientists, drug delivery and drug disposition scientists, as well as clinicians involved in designing and developing novel therapeutics for the back of the eye diseases. This book is also relevant for students in various disciplines including ophthalmology, pharmaceutical sciences, drug delivery, and biomedical engineering.
  • Produktdetails
  • AAPS Advances in the Pharmaceutical Sciences Series Vol.2
  • Verlag: Springer, Berlin
  • Artikelnr. des Verlages: 12778485
  • Erscheinungstermin: 3. März 2011
  • Englisch
  • Abmessung: 247mm x 167mm x 40mm
  • Gewicht: 1080g
  • ISBN-13: 9781441999191
  • ISBN-10: 1441999191
  • Artikelnr.: 33173094
Autorenporträt
Uday B. Kompella, Ph.D. has been an independent faculty member in the field of drug delivery for 17 years, with ocular drug delivery being a key research focus. Prior to joining University of Colorado in 2008, he served as a faculty member at University of Nebraska for 10 years and at Auburn University for 4 years. Dr. Kompella's research, published in over 100 peer-reviewed articles, is focused on developing new drug and gene delivery approaches for treating neovascular diseases including diabetic retinopathy, age-related macular degeneration, and cancer. Dr. Kompella developed and assessed several drug delivery systems including functionalized nanoparticles, nanoporous microparticles, microparticles, injectable implants, dendrimers, liposomes, and in situ forming gels for ophthalmic applications. Dr. Kompella is a Fellow of the American Association of Pharmaceutical Scientists (2005) and the Association for Research in Vision and Ophthalmology (2010). He was recognized as a Distinguished Scientist in 2006 and as a Distinguished Teacher in 2003 at University of Nebraska Medical Center. Henry F. Edelhauser, Ph.D. is a world leader in ophthalmic drug delivery, with an academic career spanning over 4 decades in ophthalmic research. After serving as a faculty member at the Medical College of Wisconsin (1966-1989) as an assistant, associate and then full professor, Dr. Edelhauser joined Emory University in 1989 as the Ferst Professor of Ophthalmology and Director of Ophthalmic Research. Dr. Edelhauser published over 230 peer-reviewed articles in the areas of ophthalmic drug delivery, surgical pharmacology, corneal physiology, and ocular toxicology. Dr. Edelhauser made pioneering contributions towards transcorneal, transscleral, and suprachoroidal drug delivery to the eye. During 1990-91, Dr. Edelhauser served as the president of the Association for Research in Vision and Ophthalmology (ARVO).  In 1999 he was awarded the Castroviejo Medal and the Alcon Research Award. In 2000, he received the senior achievement award from the American Academy of Ophthalmology. In 2005, Dr. Edelhauser was recognized with the Procter medal, ARVO's highest honor for his outstanding ophthalmic translational research from basic science to clinical applications. Henry F. Edelhauser, Ph.D. is a world leader in ophthalmic drug delivery, with an academic career spanning over 4 decades in ophthalmic research. After serving as a faculty member at the Medical College of Wisconsin (1966-1989) as an assistant, associate and then full professor, Dr. Edelhauser joined Emory University in 1989 as the Ferst Professor of Ophthalmology and Director of Ophthalmic Research. Dr. Edelhauser published over 230 peer-reviewed articles in the areas of ophthalmic drug delivery, surgical pharmacology, corneal physiology, and ocular toxicology. Dr. Edelhauser made pioneering contributions towards transcorneal, transscleral, and suprachoroidal drug delivery to the eye. During 1990-91, Dr. Edelhauser served as the president of the Association for Research in Vision and Ophthalmology (ARVO).  In 1999 he was awarded the Castroviejo Medal and the Alcon Research Award. In 2000, he received the senior achievement award from the American Academy of Ophthalmology. In 2005, Dr. Edelhauser was recognized with the Procter medal, ARVO's highest honor for his outstanding ophthalmic translational research from basic science to clinical applications. Henry F. Edelhauser, Ph.D. is a world leader in ophthalmic drug delivery, with an academic career spanning over 4 decades in ophthalmic research. After serving as a faculty member at the Medical College of Wisconsin (1966-1989) as an assistant, associate and then full professor, Dr. Edelhauser joined Emory University in 1989 as the Ferst Professor of Ophthalmology and Director of Ophthalmic Research. Dr. Edelhauser published over 230 peer-reviewed articles in the areas of ophthalmic drug delivery, surgical pharmacology, corneal physiology, and ocular toxicology. Dr. Edelhauser made pioneering contributions towards transcorneal, transscleral, and suprachoroidal drug delivery to the eye. During 1990-91, Dr. Edelhauser served as the president of the Association for Research in Vision and Ophthalmology (ARVO).  In 1999 he was awarded the Castroviejo Medal and the Alcon Research Award. In 2000, he received the senior achievement award from the American Academy of Ophthalmology. In 2005, Dr. Edelhauser was recognized with the Procter medal, ARVO's highest honor for his outstanding ophthalmic translational research from basic science to clinical applications.
Inhaltsangabe
Selection of Drug Delivery Approaches for the Back of the Eye: Opportunities and Unmet Needs.- Microdialysis for Vitreal Pharmacokinetics.- Fluorophotometry for Pharmacokinetic Assessment.- Systemic Route for Retinal Drug Delivery: Role of the Blood-Retinal Barrier.- Topical Drug Delivery to the Back of the Eye.- Principles of Retinal Drug Delivery from Within the Vitreous.- Transscleral Drug Delivery.- Suprachoroidal and Intrascleral Drug Delivery.- Advances in Biodegradable Ocular Drug Delivery Systems.- Microparticles as Drug Delivery Systems for the Back of the Eye.- Nanotechnology and Nanoparticles.- Hydrogels for Ocular Posterior Segment Drug Delivery.- Refillable Devices for Therapy of Ophthalmic Diseases.- Targeted Drug Delivery to the Eye Enabled by Microneedles.- Ocular Iontophoresis.- Drug and Gene Therapy Mediated by Physical Methods.- Protein Drug Delivery and Formulation Development.- Drug Suspension Development for the Back of the Eye.- Regulatory Considerations in Product Development for Back of the Eye.- Clinical Endpoints for Back of the Eye Diseases.- Druggable Targets and Therapeutic Agents for Disorders of the Back of the Eye.- Development of Bile Acids as Anti-Apoptotic and Neuroprotective Agents in Treatment of Ocular Disease.